Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.

Background: In a phase II study, we showed that temozolomide (TMZ) was tolerable and active in heavily pre-treated patients with advanced colorectal cancer (CRC) and MGMT methylation. A schedule of dose-dense TMZ may have enhanced activity due to the higher cumulative dose and induction of MGMT depl...

Descripción completa

Detalles Bibliográficos

Publicado en:	Targeted Oncology Vol. 11; no. 3; pp. 337 - 344
Autores principales:	Pietrantonio, Filippo, de Braud, Filippo, Milione, Massimo, Maggi, Claudia, Iacovelli, Roberto, Dotti, Katia, Perrone, Federica, Tamborini, Elena, Caporale, Marta, Berenato, Rosa, Leone, Giorgia, Pellegrinelli, Alessio, Bossi, Ilaria, Festinese, Fabrizio, Federici, Stefano, Di Bartolomeo, Maria, Dotti, Katia Fiorella
Formato:	pictorial research tables/charts Journal Article
Publicado:	Springer Nature Jun2016
Acceso en línea:	Ver este registro en EBSCOhost